Plain-English translation of NCT07139743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called obe-cel for people with progressive forms of multiple sclerosis that have not responded well to other medications. The treatment involves removing some of your immune cells, modifying them in a laboratory, and then putting them back into your body to help fight the disease. Researchers want to understand if this treatment is safe and whether it can help slow or improve progressive MS.
Progressive multiple sclerosis can get worse over time even with current treatments, and some people don't respond well to standard medications. This trial exists to see if this new cell-based approach might offer hope for people whose disease has become hard to control with existing therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll first go through a screening period to confirm you're eligible. Then you'll receive a treatment called lymphodepletion (medication to temporarily reduce certain immune cells) to prepare your body for the new treatment. On Day 1, you'll receive a single infusion of the medication into your bloodstream. After that, you'll have regular follow-up visits and tests over several months to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Spain
United Kingdom